Cancer treatment specialist BeiGene Ltd plunged 16.4% on its Shanghai debut on Wednesday after raising $3.5 billion, hit by concerns over its valuation amid potential U.S. sanctions on Chinese biotech ... ( read original story ...)
China-U.S. Tension Mars Biotech Giant BeiGene’s Shanghai Debut
BeiGene tumbled 16% in its mainland trading debut, after raising $3.5 billion and becoming the first company to be triple-listed in New York, Hong Kong and on Shanghai’s STAR Market. ( read original story ...)
Troubles mount for Shimao Group as Shanghai exchange asks Chinese developer to explain US$259 million related party deal
The US$259 million sale of a property management business by Shanghai Shimao, a unit of Shimao Group, has caught the attention of the Shanghai Stock Exchange Shimao Group also plans to cancel ... ( read original story ...)
American Biotech Billionaire’s BeiGene Achieves Listing Milestone But Drops 16% In Shanghai Debut
Shares dropped more than 16% from their IPO price amid worries about possible U.S. delisting of Chinese businesses. BeiGene, led by American billionaire entrepreneur John Oyler, raised the equivalent ... ( read original story ...)
Biotech BeiGene slides in Shanghai after US$3.5 billion STAR debut
Cancer treatment specialist BeiGene Ltd plunged 16.4per cent on its Shanghai debut on Wednesday after raising US$3.5 billion, hit by concerns over its valuation amid potential U.S. sanctions on ... ( read original story ...)
End of an era for Shanghai restaurant icon
After two decades, pioneering Australian restaurateur Michelle Garnaut has decided to close the doors of her iconic M on the Bund restaurant in Shanghai. ( read original story ...)
Hong Kong shares lead losses as investors digest Chinese economic data; biotech firm BeiGene debuts in Shanghai
Asia-Pacific markets were mostly down Wednesday, with Chinese markets declining as investors digested key Chinese economic data. Meanwhile, Chinese biotech firm BeiGene made its debut in Shanghai. ( read original story ...)